Targets › FBIA
1 program from 1 company in 1 trial: 1 Phase 2; Infectious disease; next expected readout May 2027.
Open in Phaseline: the race on FBIA, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Global Alliance for TB Drug Development | pretomanid Prodrug converted to active TB-killing compound; bioreductive nitroimidazole inhibitor of | FBIA | Phase 2 | Tuberculosis, Pulmonary | May 2027 |
Tuberculosis, Pulmonary (1)
small molecule (1)
Global Alliance for TB Drug Development (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.